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ABSTRACT
Activin/myostatin signalling acts to induce skeletal muscle atrophy in
adult mammals by inhibiting protein synthesis as well as promoting
protein and organelle turnover. Numerous strategies have been
successfully developed to attenuate the signalling properties of these
molecules, which result in augmentingmuscle growth. However, these
molecules, in particular activin, play major roles in tissue homeostasis
in numerous organs of the mammalian body. We have recently shown
that although the attenuation of activin/myostatin results in robust
muscle growth, it also has a detrimental impact on the testis. Here, we
aimed to discover the long-term consequences of a brief period of
exposure to muscle growth-promoting molecules in the testis. We
demonstrate that muscle hypertrophy promoted by a soluble activin
type IIB ligand trap (sActRIIB) is a short-lived phenomenon. In stark
contrast, short-term treatment with sActRIIB results in immediate
impact on the testis, which persists after the sessions of the
intervention. Gene array analysis identified an expansion in aberrant
gene expression over time in the testis, initiated by a brief exposure to
muscle growth-promotingmolecules. The impact on the testis results in
decreased organ size as well as quantitative and qualitative impact on
sperm. Finally, we have used a drug-repurposing strategy to exploit the
gene expression data to identify a compound – N6-methyladenosine –
that may protect the testis from the impact of the muscle growth-
promoting regime. This work indicates the potential long-term harmful
effects of strategies aimed at promoting muscle growth by attenuating
activin/myostatin signalling. Furthermore, we have identified a
molecule that could, in the future, be used to overcome the
detrimental impact of sActRIIB treatment on the testis.
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INTRODUCTION
Skeletal muscle is the largest organ found in the human body, in
which it can account for ∼50% of the entire mass. As well as
facilitating movement, this organ performs a variety of additional
roles, including protecting internal organs, maintaining body
posture, preserving constant body temperature, and assisting
movement in cardiovascular and lymphatic vessels. Skeletal
muscle is a highly adaptable organ that changes not only its mass
but also its composition to meet the physiological needs of the body
(Matsakas and Patel, 2009). Furthermore, skeletal muscle
undergoes a huge degree of maintenance to sustain its functional
capabilities through a programme of organelle surveillance and
protein turnover. It has been estimated that an average adult
weighing 70 kg has a daily protein turnover of ∼420 g per day, a
vast amount of which takes place in skeletal muscle (Waterlow and
Jackson, 1981; Slevin et al., 1991). Huge advances have been
made in our molecular understanding of the mechanisms that
control muscle mass, which have identified three key processes
(protein synthesis, protein breakdown and autophagy) that act to
keep this organ in an optimal functional state, which involve
balancing hypertrophic and atrophy-promoting activities (Sandri
et al., 2004).
Given that skeletal muscle performs so many vital functions, it is
hardly surprising that diseases manifest when mechanisms that
control its homeostasis become imbalanced. Perturbations can be
induced by genetic changes in molecules that control muscle
structure and function. One of the best studied mediators of this
class of change is Duchenne muscular dystrophy (DMD), caused by
mutations in the dystrophin gene, which encodes a molecule that
acts to prevent contraction-mediated cell damage. However, it is
likely that much of the population will experience issues related to
muscle through the process of sarcopenia, age-related muscle loss.
This is a very significant problem especially in the developing
world, where there is an unprecedented increase in the proportion of
elderly people. Sarcopenia increases both morbidity and mortality
rates (Sobestiansky et al., 2019) and puts a tremendous burden on
the economy. The hospitalisation-associated costs amount to over
$19 billion per year in the USA alone (Goates et al., 2019). Given
these facts, it is understandable why great efforts were made to
develop therapies to treat muscle-wasting conditions.
We and others have focused on manipulating the activin/
myostatin signalling pathway to promote growth, following the
discovery that these molecules are potent inhibitors of skeletal
muscle hyperplasia and hypertrophy (McPherron et al., 1997; Lee
andMcPherron, 2001;Matsakas et al., 2009; Alyodawi et al., 2019).
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This axis is an attractive therapeutic target as the ligands mediating
muscle growth inhibition are secreted by cells, thereby raising the
possibility for systemic route interventions. Several approaches
have been successfully developed that attenuate activin/myostatin
signalling and lead to robust muscle growth in adult mammalian
experimental models. These include the use of activin/myostatin-
binding proteins, such as follistatin, and receptor-blocking
antibodies (Amthor et al., 2004; Lach-Trifilieff et al., 2014).
As an alternative, we have developed an activin/myostatin ligand
trap (sActRIIB), which comprises the extracellular portion of the
activin type IIB receptor (ActRIIB; also known as ACVR2B), as
well as modifications that promote peptide stability. In a series of
studies, we have shown that this molecule induces robust muscle
growth in a matter of a few weeks when systemically administered
into mice irrespective of their age, disease state or metabolic
condition (Relizani et al., 2014; Alyodawi et al., 2019; Omairi et al.,
2016). The utility of these molecules as therapies for muscle-
wasting conditions, however, needs to be carefully scrutinised,
because the activin/myostatin signalling pathways are deployed for
the homeostasis of numerous organs and sActRIIB has broad
ligand-binding properties, with ligands including members of the
bone morphogenetic protein (BMP) family (Greenwald et al.,
2003). This line of thinking has been supported in primate studies,
which reported sActRIIB-induced changes in the spleen and
pancreas and glucose homeostasis (Latres et al., 2017).
Recently, we have shown that, while promoting muscle growth,
sActRIIB attenuated the development of the testis (Vaughan et al.,
2020a,b). In these studies, we showed that, soon after its
administration, sActRIIB inhibited testis development and function
when it was injected into mice at any stage of their post-natal life, as
well as inhibited testis development in two mice models of DMD.
Importantly, the long-term consequence of sActRIIB on muscle and
testis development remained unexplored.
In this study, we aimed to determine the molecular mechanisms
underpinning the testis phenotype induced by sActRIIB treatment,
as well as utilise a bioinformatics-based approach to identify readily
available compounds that would mitigate this phenotype. We
hypothesised that the effect of a sActRIIB regime on testicular
molecular signature would be short term and reversible after the end
of the intervention, resembling the effects on skeletal muscle. We
used a microarray-based approach to develop a transcriptomic
profile of the testis to investigate the short- and long-term sActRIIB
action. Our results show that sActRIIB only promotes short-lived
muscle growth, in contrast to a persistent testicular phenotype,
which at the molecular level inflates over time. Molecular changes
induced by sActRIIB were predicted to impact on microtubule
function, which was verified by ultrastructural examination of
sperm. Finally, Connectivity Map (CMAP)-based drug repurposing
(Lamb et al., 2006) identified one molecule that would potentially
attenuate the testis phenotype in a temporal-independent manner.
RESULTS
We have previously shown that sActRIIB promoted robust muscle
growth in several mouse models (Alyodawi et al., 2019). In keeping
with those results, we here showed that a short treatment (∼20 days)
induced muscle growth, without any significant changes in body
weight (Fig. 1A-C; Fig. S1A-D). However, even this short treatment
caused a decrease in testis weight (Fig. 1D). Examination of
histological sections of testis from mouse treated at post-natal day
(P)17 to P37 revealed that the seminiferous tubular area was
reduced, as was the differentiation thickness and the tubule lumen
area (Fig. 1E-G). We then investigated whether the reduction in
testis weight in adult mice caused by sActRIIB treatment of pre-
pubertal mice was of a permanent nature or whether this effect was
reversible. To that end, we injected mice until P35 and examined
tissues at P120 (Fig. 1H). Interestingly, at this time point, there was
no difference in body weight or muscle mass between the two
cohorts (Fig. 1I,J). However, the testes of sActRIIB-treated mice
were lighter than those of controls (Fig. 1K), and three metrics of
testicular development (tubule area, lumen area, differentiation
thickness) were reduced (Fig. 1L-N). We next analysed whether the
decrease in tubule area, lumen area and differentiation thickness was
a read out of a decrease in testis weight. Therefore, we calculated the
ratio of these parameters normalised to the weight of the testis and
then compared the ratios for tissues from control mice to those from
treated animals. Interestingly, the decrease in the measures of tubule
area, lumen area and differentiation thickness appears to reflect the
decrease in testis size (Fig. S1E-J). However, the ratio between
lumen area and testis weight at P120 was significantly different
between control and sActRIIB-treated mice, indicating an effect of
the sActRIIB treatment (Fig. S1H). Hence, most, but not all, internal
decreases in tissue architecture can be explained by the smaller size
of the overall testis.
We next investigated the possible causes for the change in testis
size following sActRIIB treatment by examining key signalling
pathways thought to be impacted by activin/myostatin signalling. To
test whether sActRIIB treatment effectively reduces activin signalling
in the testis, we performed western blotting with protein lysates
prepared from P37 and P120 mice treated with either sActRIIB or
PBS. As shown in Fig. 2, there was a significant reduction in the ratio
of phospho (p)SMAD2/SMAD2 (the most proximal signalling effect
after ActR engagement) in testes from sActRIIB-treated mice at P37,
but this effect does not persist at P120 (Fig. 2A,C). This, therefore,
suggests that the proximal effects of TGFβ signalling inhibitionmight
be the cause of spermatogenic defects as discussed above. The AKT
signalling pathway was shown to be induced in a model of increased
activin activity, in which the testis size is increased (Oldknow et al.,
2013). Hence, we investigated whether, in our model of reduced
activin action and reduced testicular size, AKT activation is reduced.
Interestingly, in our studies, we did not find any reduction in AKT
activity, suggesting that AKT signalling might not play an important
role in the testes of mice treated with sActRIIB (Fig. 2A,B).We failed
to identify any significant changes in pERK/ERK (also known as
MAPK) at the early time point, but they were reduced by treatment at
P120 (Fig. 2A,D).
To identify the differential genome-wide gene expression patterns
potentially responsible for the changes in testis size, microarray
analyses from micro-dissected testes of sActRIIB-treated and
control animals were performed. Analysis of the microarray by
principal component analysis (Fig. 3A) revealed differences in
genome-wide gene expression patterns between the sActRIIB-
treated and control animals at P37 that became more prominent at
P120, suggesting a strong impact of the sActRIIB injection.
Notably, gene expression in the testes of control animals at P37
and P120 clustered closer with that of the sActRIIB-treated animals
at P37 than with that of the sActRIIB-treated animals at P120.
Overall, we detected 355 differentially expressed genes between
sActRIIB-treated and control animals at P37 (98 upregulated and
257 downregulated genes), whereas 1801 genes showed a
differential expression pattern at P120 (1003 upregulated and 798
downregulated genes). Volcano plots comparing gene expression
between control and sActRIIB-treated mice further emphasised that
the gene expression patterns exhibit more differences at P120 than at
P37 (Fig. 3B,C). Importantly, as evidenced by the heat map in
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Fig. 3D, at both time points, the arrays for each experimental group
yielded similar data. A distinct gene expression pattern was
observed, differentiating the sActRIIB-treated and control animals
at both time points (Fig. 3D).
A more in-depth examination into the most differentially
expressed genes between sActRIIB-treated mice and control
animals at P37 revealed strong downregulation of multiple genes
including Car3, Cml5 (also known as Nat8f5) and Cd36, but strong
Fig. 1. sActRIIB causes a reduction in testicular development in mice at P37 and P120. (A) Schematic of experimental design for P37 treatment. Red
arrows indicate injection of 10 mg/kg sActRIIB; blue arrow indicates time of cull. (B-G) For P37, body weight (B), gastrocnemiusmass (C), testis mass (D), average
tubule area (E), average lumen area (F) and average differentiation thickness (G) in the PBS- and sActRIIB-treated mice. n=7 PBS-treated male mice, n=7
sActRIIB-treated male mice. (H) Schematic of experimental design for P120 treatment. Red arrows indicate injection of 10 mg/kg sActRIIB; blue arrow
indicates time of cull. (I-N) For P120, body weight (I), gastrocnemius mass (J), testis mass (K), average tubule area (L), average lumen area (M) and average
differentiation thickness (N) in the PBS- and sActRIIB-treated mice. n=4 PBS-treated male mice, n=4 sActRIIB-treated male mice. Unpaired Student’s t-test was
used to determine statistical significance. *P<0.05, **P<0.01.
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upregulation of Wfdc17, Gm4047 and Hgh1, in sActRIIB-treated
mice (Fig. 3E). Consistent with the principal component analysis
(PCA), the differences in gene expression at P120 were more
pronounced and revealed strong upregulation of Malat1, but strong
downregulation of Klk1b24 and Klk1b27, in animals treated with
sActRIIB (Fig. 3F).
Volcano plot analysis of the differential expression pattern at P37
versus P120 in control animals showed less prominent differences.
Notably, more pronounced differences were observed when directly
comparing the expression pattern in testes of animal treated with
sActRIIB at both respective time points (Fig. 4A,B). An in-depth
analysis showed strong downregulation ofMalat1 at P120 compared
to P37 in the control group. In contrast, Malat1 was upregulated at
P120 compared to P37 in the sActRIIB-treated group (Fig. 4C,D).
Next, in order to identify potential biological processes and
canonical pathways responsible for the differences between the
experimental groups, we performed an analysis of down- and
upregulated canonical pathways and pathways involved in disease
and specific cellular functions using the Ingenuity Pathway
Analysis (IPA) tool (Figs S2 and S3). Here, we demonstrated
strong downregulation of multiple signalling pathways involved in
cell proliferation in the sActRIIB group at P37, including NF-κB
and IL-6 signalling. In contrast, IPA revealed strong upregulation of
the negative regulator of proliferation (Lu et al., 2016) PTEN
compared to the control group at P37 (Figs S2 and S3).
As IPA revealed an impact of sActRIIB on several processes and
signalling pathways linked to cell proliferation, an in-depth analysis
of genes linked to cell proliferation was performed. A heat map
analysis of the respective gene profiles revealed profound
differences between the gene expression patterns of control and
sActRIIB-treated animals at P120, whereas less prominent effects
were revealed at P37 (Fig. 5).
The bioinformatic analysis of gene expression demonstrated that
key cellular processes and pathways were affected by sActRIIB
treatment. We next examined the testes to determine whether these
RNAmeasurements affected cellular processes that are evident at the
tissue level. We first assessed cell proliferation in the testes, by
quantifying the number of proliferating cell nuclear antigen (PCNA)-
expressing cells. Our studies showed that proliferating cells were
located adjacent to the basement membrane in the control and
sActRIIB-treated samples at both time points (Fig. 6). However,
there was a reduction in the number of proliferating cells at P37 but
not at P120 (Fig. 6F,P). We next counted the number of
spermatogonial stem cells (SSCs) as they give rise to proliferating
cells, A and B type spermatogonial cells. To this end, we counted the
number of PLZF (also known as ZBTB16)-positive cells per tubule
in control and sActRIIB-treated samples. However, we failed to
detect any impact of sActRIIB treatment on this parameter at either
time point (Fig. 6G,Q). Next, we examined the impact of sActRIIB
treatment on the capacity of preleptotene spermatocyte to go into
meiosis by assessing Stra8 staining. Again, no difference was found
at either time point following sActRIIB treatment (Fig. 6H,R).
Thereafer, we counted the number of Sertoli cells, recognised by
Sox9 expression, and found no differences in this parameter among
the sActRIIB-treated group and controls (Fig. 6I,S). Counting of
mature sperm is not possible at P37, as at this age the first wave of
spermatogenesis is not completed and therefore these cells have not
yet developed. However, this is possible at P120. We found that the
number of mature sperm in the lumen, as judged by the development
of sperm tails, was significantly reduced by sActRIIB treatment at
P120 (Fig. 6O,O′,T).
Because pathological changes in the cell cytoskeletal architecture
are often associated with testicular dysfunction (Johnson, 2014), a
bioinformatic analysis of gene expression associated with the
cytoskeleton was performed. A global heat map of the respective
gene expression between the groups revealed strong effects of
sActRIIB treatment at P120, with consistent levels of gene
expression between the individual animals in the group (Fig. S4).
Fig. 2. Altered signalling in testis upon
sActRIIB treatment. (A) Immunoblot
analyses of testis lysates from P35 (young) or
P120 (adult) mice treated with PBS or
sActRIIB (see Materials and Methods for
treatment times) for either phosphorylated (p)
or total target proteins (AKT, SMAD2 and
ERK) as indicated. (B-D) Bar graphs
representing densitometric quantification of
phosphorylated target protein normalised to
total target protein from the western blotting
experiments shown in A: pAKT/AKT (B),
pSMAD2/SMAD2 (C) and pERK/ERK (D).
Unpaired Student’s t-test was used to
determine statistical significance. n=3,
*P<0.05.
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Fig. 3. See next page for legend.
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Notably, a very similar gene expression pattern was observed
between the sActRIIB and control groups at P37. A more detailed
analysis of genes involved in microtubule cytoskeleton organisation
revealed a very similar expression pattern, with strong differences
between the sActRIIB-treated and control group at P120, and a
relatively homogenous expression pattern if the sActRIIB-treated
and the control group were compared at P37. Similarly, subsequent
analysis of genes involved in microtubule polymerisation and
depolymerisation, actin-mediated cell contraction and actin-myosin
filament sliding showed strong effects of sActRIIB at P120 (Fig. S5),
suggesting that the treatment affects cytoskeletal organisation and
function.
The bioinformatic analysis predicted changes in microtubule
function and structure. These molecules are key in the development
of normal functional sperm. We examined the ultrastructure of
sperm, as well as their activity, to determine whether bioinformatic
predictions were translated into a biological setting. Hence, we
isolated sperm from the epididymis of P120 mice. Transmission
electron microscopy images showed sperm from control mice to
have normal morphology, i.e. acrosome, large nuclei and sheets of
mitochondria (Fig. 7A). In contrast, the sperm from sActRIIB-
treated mice showed numerous abnormalities, including many
immature sperm, sperm with two or more nuclei, and doubled mid-
pieces containing two 9+2 microtubule arrangements (Fig. 7B-D).
The number of sperm recovered from the epididymis of sActRIIB-
treated mice was significantly lower than that from control mice
(Fig. 7E). We also tracked sperm using time-lapse microscopy.
Analysis of the video captures revealed a deficit in sperm motility
from sActRIIB-treated mice compared to controls (Fig. 7F).
The bioinformatic analysis also predicted changes in cell survival
and death.We investigated this further by profiling the expression of
cleaved poly (ADP-ribose) polymerase-1 (PARP-1), a marker of
cell death. Although this marker was present in the testis, its
abundance was not changed as a consequence of sActRIIB
treatment (Fig. S3A-C).
To determine the cohort of CMAP-derived repurposed
compounds that could potentially antagonise the phenotypic
effects of the treatments described herein, we first assayed the set
of genes regulated by each treatment at P37 and P120 compared to
the vehicle control (PBS). These investigations identified 1441
genes that were statistically significantly regulated [435 upregulated
and 1006 downregulated (treatment versus control P<0.05; fold
change,−2 or >2)] at P37. Using a similar approach on a set of 5122
genes, several genes were found to be regulated significantly by the
treatment at P120 compared to the PBS vehicle control [1574
upregulated and 3548 downregulated (treatment versus control
P<0.05; fold change, −2 or >2)]. These data demonstrate that, at
both P37 and P120, there is a substantial and robust gene expression
response (Fig. 8A). We next sought to determine the potential set of
US Food and Drug Administration (FDA)-approved compounds
that either correlated or anti-correlated with the collection of genes
differentially expressed at each of these time points using a CMAP
approach. Briefly, genes differentially expressed at P37 or P120
were ranked based on their fold change (i.e. treatment versus PBS
control signatures) prior to surveying the CMAP Drug Profile
Database as described in Williams et al. (2019). These
interrogations revealed a compendium of FDA-approved drugs
that either positively or negatively correlated with the P37 and P120
biological signatures. The top five sets of drugs, based on the
magnitude of positive and negative correlation, are shown in
Fig. 8A. We were primarily interested in identifying the set of drugs
with the potential of ameliorating the impact of the treatment
described here (i.e. those drugs for which CMAP gene expression
profiles anti-correlate with the biological signatures). Accordingly,
the top 25 compounds were ranked by the magnitude of anti-
correlation and associated significance, described in Table S2
(Williams et al., 2019). Analysis of these data revealed that 29
compounds showed anti-correlating profiles at P37 compared to 86
at P120 (Fig. 8B). We next sought to determine whether any of the
compounds were able to ‘antagonise’ the changes in the treatment-
driven gene expression at both P37 and P120; these investigations
yielded only one compound, N6-methyladenosine, with ‘anti-
correlative’ features, at both time points (Fig. 8B).
To summarise, our findings indicate that the treatment described
here induces large-scale genome-wide gene expression differences
at both P37 and P120 following initial exposure. Furthermore, we
have applied CMAP-based genomic drug repurposing to identify a
set of FDA-approved candidate compounds that potentially have the
capacity to restore the phenotypic impact of the treatment.
Interestingly, our data provide evidence that N6-methyladenosine
has the capacity to ameliorate the dysregulation of genes driven by
the treatment at both P37 and P120, and thus represents a strong
candidate for future drug-based interventional approaches.
DISCUSSION
Manipulating the activin/myostatin signalling pathway to promote
muscle growth has received much attention in the past decade as our
understanding of this signalling cascade has increased, which has
inevitably led to the identification of therapeutic targets. We and
others have developed readily injectable molecules that attenuate
signalling through one of the key cell surface receptors, ActRIIB,
which plays a major role in activin/myostatin signal transduction.
These molecules all promote rapid muscle growth (Alyodawi et al.,
2019; Omairi et al., 2016; Rooks et al., 2017). However, we and
others have documented that these interventions can also result in
unwanted side effects (Campbell et al., 2017). In particular, we have
focused, in a number of studies, on the detrimental effect of
sActRIIB on testis development that accompanies muscle growth
(Vaughan et al., 2020a,b). Here, we examine the molecular basis
underpinning the impact of sActRIIB on the testis.
We found that short-term treatment had a positive impact on
muscle growth but was accompanied by a stunting of testis
development, a result in keeping with our previous findings
Fig. 3. Bioinformatic comparison of the gene expression in sActRIIB-
treated mice and control animals. (A) Principal component 3D-analysis
(PCA) of the gene expression data set. Each dot represents a sample.
(B,C) Volcano plot analysis showing log2 fold change and P-value of each
transcript. Each gene is represented by a dot on the graph. The x-axis
represents the log2 value of fold change, and the y-axis represents the
t-statistic as log10 P-value. Coloured dots represent the genes that are ≥2-fold
upregulated (red) or downregulated (blue) with a P-value lower than 0.05. In
total, 355 genes were found to be differentially expressed in sActRIIB-treated
animals and controls at P37 (B), and 1801 genes were found to be differentially
expressed at P120 (C). (D) Hierarchical clustering. Each column represents
one individual animal. The colour and intensity of the boxes are used to
represent changes (not absolute values) in gene expression. Red represents
upregulated genes; blue represents downregulated genes; black represents
unchanged expression. Only genes significantly (P<0.05) differentially
expressed with a 3-fold minimal change in expression are illustrated. (E,F)
Heat map representations of differentially expressed transcripts at P37 (E) and
P120 (F), with the highest degree of change sorted according to z-score
ranking. Euclidean distance measures and average leaf clustering were
applied to rows. The list of differentially altered transcripts with the highest
degree of change of expression in each condition is shown in the column on the
right (corresponding gene symbols). The colours correspond to the z-score,
ranging from green (low expression) to red (high expression).
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(Vaughan et al., 2020b). However, following the cessation of
sActRIIB treatment, the muscle growth phenotype was lost but the
detrimental impact on testis size remained. The temporal profile of
muscle growth following the withdrawal of sActRIIB is interesting;
both treated and control muscle weigh the same at P120 despite the
increased size of sActRIIB-treated muscle at P37, right after the
time when the treatment was stopped. The key feature here is that in
the control animals there was a phase of muscle growth, which was
not observed in the animals that had been treated with sActRIIB. It is
possible that pre-treatment with sActRIIB either prevents the muscle
growth program or that the muscle is refractory to molecules that
promote myogenic hypertrophy. Alternatively, both cohorts may
display the same amount of muscle as a consequence of
experiencing identical load following the cessation of treatment.
Future studies will explore these and other possible reasons for the
muscle phenotype.
A key issue that needs to be addressed concerns the development
of side-effects following the use of sActRIIB (or similar-acting
molecules). We are not the first to report adverse outcomes of their
use (Campbell et al., 2017), but nevertheless it is interesting that
others have not encountered such issues. This could simply be that
the focus of such studies has been on muscle, and side-effects have
been overlooked. However, it is also worth considering the context
in which we report the side-effects of sActRIIB. Here, we have used
Fig. 4. Bioinformatic comparison of testis gene expression in sActRIIB-treated mice. (A,B) Volcano plot analysis showing log2 fold change and P-value of
each transcript at P120 versus P37 in PBS-treated mice (A) and sActRIIB-treated mice (B). The x-axis represents the log2 value of fold change, and the
y-axis represents the t-statistic as log10 P-value. Coloured dots represent the genes that are ≥2-fold up- or downregulated with a P-value lower than 0.05.
Upregulated and downregulated genes are highlighted in red and blue, respectively. (C,D) Heat map representations of differentially expressed transcripts with
the highest degree of change, sorted according to z-score ranking, in PBS-treated mice (C) and sActRIIB-treated mice (D). Euclidean distance measures
and average leaf clustering were applied to rows. The list of differentially altered transcripts with the highest degree of change of expression in a given condition is
shown in the column on the right (corresponding gene symbols).
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a model to promote muscle growth in a healthy mouse, in which the
levels of muscle atrophy-inducing molecules are low when high
levels of sActRIIB have been administered. In such a scenario, we
would essentially neutralise all activin/myostatin. This scenario
could be very different in the setting of a muscle-wasting condition,
when lower levels of sActRIIB are used. We note that others have
used a similar molecule at the same concentrations but in a context
of muscle wasting without noting adverse effects on the testis
(Hawinkels et al., 2016). It is possible that, in a model of muscle
wasting, activin/myostatin levels are high and the dose of sActRIIB
used is stoichiometrically unable to completely neutralise high
amounts of the ligands, hence the adverse effect on the testis is not
seen. We suggest that, in the latter condition, the lower levels of
activin/myostatin may be sufficient for testis development but still
capable of preventing muscle atrophy. Again, future work is
planned to test this line of thinking.
We have explored the long-term impact on the testis of a limited
exposure to sActRIIB in considerable detail, both ranging from
studies of organ structure and function down to in-depth molecular
analysis. One key question we aimed to address was the nature of the
mechanisms underpinning the testis phenotype at the two time
points, specifically whether the molecular mechanisms initiated by
sActRIIB remained the same over time or whether they evolved.
The protein expression data were our first indication that the
phenotype evolved; initially there was a decrease in testicular
pSMAD2 levels induced by sActRIIB but later these were
normalised. However, a converse effect was detected when we
profiled levels of pERK. It is well established that several signalling
Fig. 5. Heat map representations of differentially
expressed transcripts within the gene ontology
category ‘Regulation of cell proliferation’.
Euclidean distance measures and average leaf
clustering were applied to rows. The experimental
conditions are indicated on the bottom. Each column
represents one individual animal.
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Fig. 6. Histological and immunocytochemical analysis of testis. (A-I) Tissue from P37 mice. (A,A′) H&E staining of seminiferous tubules in PBS- (A)
and sActRIIB-treated (A′) mice, showing smaller tubules in the sActRIIB-treated mice. (B,B′) PCNA-positive cells in the tubules of PBS- (B) and sActRIIB-treated
(B′) mice, showing a reduction in PCNA-positive cells in the sActRIIB-treatedmice. (C,C′) PLZF-positive cells in the tubules of PBS- (C) and sActRIIB-treated (C′)
mice. (D,D′) Stra8-positive cells in the tubules of PBS- (D) and sActRIIB-treated (D′) mice. (E,E′) Sox9-positive cells in the tubules of PBS- (E) and
sActRIIB-treated (E′) mice. (F) Quantification of PCNA-positive cells per tubule. (G) Quantification of PLZF-positive cells per tubule. (H) Quantification of
Stra8-positive cells per tubule. (I) Quantification of Sox9-positive cells per tubule. n=7 PBS-treated male mice, n=7 sActRIIB-treated male mice. (J-T) Tissue from
P120 mice. (J,J′) H&E staining of seminiferous tubules in PBS- (J) and sActRIIB-treated (J′) mice, showing smaller tubules in the sActRIIB-treated mice.
(K,K′) PCNA-positive cells in the tubules of PBS- (K) and sActRIIB-treated (K′) mice, showing a reduction in PCNA-positive cells in the sActRIIB-treated mice.
(L,L′) PLZF-positive cells in the tubules of PBS- (L) and sActRIIB-treated (L′) mice. (M,M′) Stra8-positive cells in the tubules of PBS- (M) and sActRIIB-treated (M′)
mice. (N,N′) Sox9-positive cells in the tubules of PBS- (N) and sActRIIB-treated (N′) mice. (O,O′) AQP3-positive cells in the tubules of PBS- (O) and
sActRIIB-treated (O′) mice. (P) Quantification of PCNA-positive cells per tubule. (Q) Quantification of PLZF-positive cells per tubule. (R) Quantification of
Stra8-positive cells per tubule. (R) Quantification of Sox9-positive cells per tubule. (T) Quantification of AQP3-positive tubules as a percentage of total tubules.
n=4 PBS-treated male mice, n=4 sActRIIB-treated male mice. Scale bars: 50 µm. Unpaired Student’s t-test was used to determine statistical significance.
*P<0.05. H&E, Haemotoxylin and Eosin; PCNA, proliferating cell nuclear antigen; PLZF, promyelocytic leukemia zinc finger; Sox9, SRY-box 9; Stra8, stimulated
by retinoic acid 8.
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pathways can be activated through the ALK receptors (Massy and
Drueke, 2016). Interestingly, our work shows that the ligand trap
does not induce activation of the AKT pathway in testis, which
contrasts with the situation in muscle, where the activation of this
pathway underpins the development of muscle hypertrophy. It has
been postulated that the identity of the activated cascade may be
determined by ligand concentration or by the presence of specific
co-receptors, as well as other factors. Irrespective of what is driving
signalling in the tissues, we can conclude that there are changes in
signalling activity over time.
The gene expression data have revealed another key feature
underpinning the testis phenotype. We show that the number of
Fig. 8. Connectivity Map (CMAP)-based drug identification. (A) Differential gene expression analysis between P37 and P120 conditions are represented as
volcano plots (P>0.01, fold change >±2) and top five correlate and anti-correlate CMAP-derived drug matches at each time point. (B) Venn diagram and
CMAP scores of the unique and common drug compound between P37 and P120.
Fig. 7. sActRIIB treatment disrupts spermatozoa morphology, sperm concentration and sperm speed when administered to CD1 mice from P17 until
P120. (A) Transmission electron microscopy of sperm revealed normal spermatozoa morphology in mice treated with vehicle. Acrosome (arrowhead), nuclei
(asterisk), midpiece with mitochondrial sheath (arrows), and numerous longitudinal and cross sections of the principal and end pieces showing regular
arrangement of microtubules (mt) and outer dense filaments, are shown. (B-D) In the sActRIIB group, few intact spermatozoawere detectable. Instead, a lot of cell
debris and displastic sperm was detectable (asterisks, B). This included immature, round sperm containing doubled nuclei (arrowheads, B), with normal
acrosomes (arrows, C) and doubled midpieces (arrows, B,D). Spermatozoa also displayed degenerating mitochondria (mt, D) and disarranged microtubules (D)
and outer dense filaments. Scale bars: 1 µm. (E) Sperm concentration at 17 weeks of age. (F) Sperm speeds at 17 weeks of age. n=6 PBS-treated male CD1
mice, n=6 sActRIIB-treated male CD1 mice. Unpaired Student’s t-test was used to determine statistical significance. ***P<0.001.
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differentially expressed genes increases greatly with time. There
were 257 genes that showed greater than 2-fold difference at the
early time point, whereas this number had risen to over 1800 by
P120. This type of amplification of a molecular phenotype has
previously been noted in a number of other studies [e.g. during
ageing (Bryois et al., 2017)], and these studies have shown that the
deregulation of a relatively small number of genes initiates large-
scale changes owing to their impact on the expression of key
molecules including transcription factors, regulators of epigenetic
modifiers and genomic stability. Although the number of changes in
gene expression increased greatly over time, we suggest that the
actual number could be even higher as we have profiled the entire
tissue. Herein, it is highly likely that cell-specific changes could be
masked by one gene being upregulated in a certain cell type while it
is downregulated in another, leading to the erroneous conclusion
that it has not changed. This issue is highlighted by the
bioinformatic analysis of genes associated with cell proliferation.
Here, we showed that that there was a major difference in the profile
of transcripts associated with this cellular activity at the late time
point. However, there was no change in the number of cells in the
cell type that was the one of the most mitotically active (SSCs).
Future studies are planned using single-cell transcriptomics, which
will not only circumvent this problem but will ultimately identify
the cell types affected by sActRIIB. Nevertheless, our work shows
that a brief exposure to sActRIIB initiates a cascade of secondary
changes.
The bioinformatic analysis made predictions related to the
expression of genes associated with cytoskeletal function, in
particular microtubule organisation following a systemic treatment
with sActRIIB. These predictions were borne out by our studies
profiling the structure and function of the sperm. One of the most
prominent features of sperm is the 9+2 microtubular organisation in
the mid-piece as well as the tail (Lehti and Sironen, 2017).
Abnormal sperm flagella have been associated with male infertility
in a number of conditions, in particular Kartagener syndrome
(Afzelius, 1976). We found that sActRIIB induced numerous
changes to the structure and function of sperm. At the ultrastructural
level, we noted cells that lacked the canonical 9+2 microtubule
organisation or tails that lacked these structures. Importantly we
showed that there was a defect in their function; sperm from
sActRIIB-treated mice showed lower motility. However, it is
important to note that microtubules play an important role not only
in sperm motility but also during their development. Microtubules
play key roles in the function of Sertoli cell structure and function
(Amlani and Vogl, 1988; Vogl, 1988), in the spermatogonia (Vogl
et al., 1995) and during their development (O’Donnell and
O’Bryan, 2014). Therefore, the deregulation of the microtubular
system is likely to have a major impact on the development of the
testes.
Bioinformatic analysis of the testis transcriptome identified not
only genes that were associated with microtubule organisation but
also those that have a major role in sperm development and
function. Two of the most highly upregulated microtubule-
associated genes were Hspa1a and Cib1. Hspa1a has been shown
to be a key spermatozoa molecule that is essential for their structural
and functional competence (Kumar et al., 2020). Furthermore, Cib1
has been shown to be essential for mouse spermatogenesis (Yuan
et al., 2006). A key question for future studies is how activin/
myostatin signalling regulates microtubule gene expression. There
is a dearth of information on this subject in the mammalian context.
However, there is precedent in Drosophila for such a system with a
clear link originating from the ligand (Dawdle) to the microtubule
components (Ellis et al., 2010). The latter data could be deployed as
a genetic template to investigate the link between activin signalling
and microtubular gene expression.
As well as identifying possibly molecular causes of the testis
phenotype induced by sActRIIB treatment, we have used the gene
expression profiles to identify compounds that may possibly reverse
the detrimental impacts of the intervention. Herein, we used the
CMAP platform to identify molecules that are predicted to induce
gene expression changes that are opposite to those caused by
sActRIIB. These include readily available molecules including
Benflourex, a drug with possible utility in the treatment of type 2
diabetes (Ravel and Laudignon, 1996), as well as Equilin, which is a
component of a hormone replacement therapy (Takei et al., 2016).
These drugs were predicted to be effective only at one of the two (P37
and P120) time points examined in this study.We interrogated the data
for a drug/molecule that would be effective at both time points, which
revealed the name of only one compound: N6-methyladenosine. This
is a novel medicinal compound as it is normally associated with the
molecular modification of RNA, which impacts on nuclear transport,
pre-mRNA splicing, microRNA biogenesis stability and translation
(Zhang et al., 2019). However, there are studies showing that
N6-methyladenosine has direct biological activity, including its ability
to regulate the activity of ATP receptors as well as the expression of
key enzymes (Ribeiro and Sebastião, 1984; Burke and Joh, 1985).
Although the CMAPanalysis has identified putative attenuators of the
testis phenotype, caution must be exercised in deploying some of the
molecules as they may bring about massive disruption to organismal
homeostasis [disruption of protein synthesis by the CMAP-identified
compound chlorhexidine (Pucher and Daniel, 1992)]. Nevertheless,
we believe that it is a good starting position to overcome the side
effects of sActRIIB, but one which will need to be refined, especially
by using single-cell transcriptomics data.
In summary, we have defined the molecular changes that develop
in the testis because of using a regime aimed at promoting muscle
growth. We show that short-term use of sActRIIB initiated
temporally expanding molecular changes, many of which are
predicted to impact on the structure and function of sperm. This
projection was further verified in cellular and ultrastructural profiling
to reveal abnormalities in sperm number, structure and motility.
MATERIALS AND METHODS
Ethical approval
Mouse-based experiments were performed under the auspices of a UK
project licence, conforming to the Animals (Scientific Procedures) Act
1986. All procedures were approved by the Animal Care and Ethics Review
committee of the University of Reading. Mice were sacrificed through
Schedule 1 killing.
sActRIIB-Fc production
The recombinant fusion protein was produced in house. The ectodomain
(ecd) of human sActRIIB was amplified via PCR with the primers 5′-
GGACTAGTAACATGACGGCGCCCTGG-3′ and 5′-CCAGATCTGCG-
GTGGGGGCTGTCGG-3′ from a plasmid containing the human ActRIIB
sequence (in pCR-Blunt II-TOPO AM2-G17 ActRIIB, IMAGE clone no.
40005760; The IMAGE Consortium). A human IgG1 Fc domain with a
COOH-terminal His6 tag was amplified by PCR (5′-GCAGATCTAATC-
GAAGGTCGTGGTGATCCCAAATCTTGTGAC-3′ and 5′-TCCCTGT-
CTCCGGGTAAACACCATCACCATCACCATTGAGCGGCCGCTT-3′)
from the pIgPlus expression plasmid. The subcloning of these products was
done into the pGEM-T easy (Promega) vectors, sequenced, and fused before
cloning into the expression vector pEFIRES-P (Hobbs et al., 1998). For the
final protein production, Chinese hamster ovary (CHO) cells were
transfected with the above-mentioned ActRIIBecd-FcHis6 expression
vector via lipofection (Fugene 6; Roche) and selected with puromycin
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(Sigma-Aldrich, Lyon, France). During selection, cells were grown in
Dulbecco’s modified Eagle medium supplemented with 2 mmol/l
L-glutamine, 100 μg/ml streptomycin, 100 IU/ml penicillin and 10% fetal
calf serum. For large-scale expression, cells were adapted to serum-free CD
OptiCHO medium (Gibco) supplemented with 2 mmol/l L-glutamine and
grown in suspension in an orbital shaker. Cell culture supernatants were
clarified by filtration through a 0.22-µm membrane (Steritop; Millipore).
Next, NaCl and imidazole were added, and the solution was pumped
through a Ni-loaded HiTrap Chelating column (GE Healthcare Life
Sciences-Cytiva, Uppsala, Sweden) at 4°C. Protein was eluted by raising
imidazole concentrations, dialysed against PBS, and finally concentrated
with an Amicon Ultra concentrator (30000 MWCO; Millipore). The purity
of our sActRIIB-Fc preparation after immobilised metal affinity
chromatography purification was estimated to be over 90% based on
silver-stained sodium dodecyl sulphate–polyacrylamide gel electrophoresis.
Animal maintenance
C57 strain mice were bred and maintained at the Biological Resources Unit
of the University of Reading in normal housing conditions, which included
ad libitum access to food and water. sActRIIB was administered via the
intraperitoneal route starting on P17 on a twice weekly basis at a dose of
10 mg/kg until P35. Mice were then maintained without further sActRIIB
treatment until the time of sacrifice (either P37 or P120).
Histology and immunocytochemistry
Testes were fixed in 4% paraformaldehyde for histology and
immunocytochemistry. Thereafter, tissue was processed for microtome
sectioning firstly by embedding in paraffin. Then, 8-µm sections were
produced, which were treated for antigen retrieval using 10 mM citrate
buffer and processed further as described in Vaughan et al. (2020b). Details
of primary and secondary antibodies are provided in Table S1.
Electron microscopy
Epidydimal sperm samples were centrifuged and the resulting pellet
embedded in 2% agarose for transmission electron microscopy. Thereafter,
cells/tissue samples were contrasted using 1% osmium tetroxide in PBS for
45 min at room temperature and 1% uranyl acetate (45 min at room
temperature in 70% ethanol). Agar blocks were dehydrated and embedded
in epoxy resin (Durcupan, Sigma-Aldrich, Germany). Ultrathin sections
were prepared using a Leica UC6 ultra-microtome and analysed using a
Philipps CM100 transmission electron microscope.
Bioinformatics
Genome-wide gene expression of testes from control mice (PBS) and mice
treated with the soluble form of the activin type IIB receptor (sActRIIB) at
P37 and P120 was analysed in independent triplicate using Affymetrix
GeneChip® Mouse430_2 Arrays. Raw image data were analysed with
Affymetrix® Expression ConsoleTM Software, and gene expression
intensities were normalised and summarised with the robust multiarray
average algorithm (Irizarry et al., 2003). To identify genes differentially
expressed between treated and control mice, a comparison analysis using
Affymetrix Transcriptome Analysis Console (TAC) 4.0 Software was
performed. Gene expression was considered as changed if transcript levels
between treated and control groups were differential with a 2-fold change
and a P-value of <0.05. For the pathway analysis, sets of differentially
expressed genes (corresponding to identified transcripts, |Log2FC|≥1,
q≤0.05) were assessed by Qiagen’s Ingenuity® Pathway Analysis (IPA®;
spring release 2019). Specifically, we carried out a canonical pathway,
followed by disease and function associations’ analysis. P-values, which
were ascertained by right-tailed Fisher’s exact test following Benjamini and
Hochberg correction, indicated the robustness of correlation between a
subset of differentially expressed genes of the dataset with a given biological
function. Annotations demonstrating a |z-score| >2.0 were taken into account
for the heat-map representation (predicted activation or inhibition of a given
biological function), as described by Pezzini et al. (2017). Heat maps were
drawn with Heatmapper (Babicki et al., 2016), utilizing Euclidean distance
measures with leaf clustering.
Connectivity mapping
Total RNAwas extracted from biological replicates using the Agilent Micro
RNA system as per the manufacturer’s instructions (Agilent). The integrity
of the total RNA from each sample was determined using a 2100
Bioanalyzer system in combination with a RNA pico chip as per the
manufacturer’s instructions, and RNA quantities were normalised using
Nanodrop spectrophotometric measurement. Genome-wide transcriptomic
representation from 500 pg total RNA from each sample was determined via
Affymetrix MOE430_2 GeneChips (Thermo Fisher Scientific) in
combination with Nugen Ovation WTA Pico V2 Library preparation as
per the manufacturer’s instructions. Differential expression datawere quality
controlled (e.g. PCA analysis) and analysed using the TACX software
package (Thermo Fisher Scientific) as per the manufacturer’s guidelines.
The microarray data in this study were summarised and normalised using
MAS5 pre-processing. Statistically significant differentially expressed gene
lists [P<0.05; fold change >±2] were submitted for CMAP analysis as
described previously (Williams, 2013).
Statistical analysis
Data are presented as mean±s.e. Student’s t-test for independent variables
was used to identify the differences between two groups. Datawere analysed
to establish whether they followed a normal distribution pattern. Statistical
analysis was performed in GraphPad Prism 5 with statistically significant
differences considered at P<0.05. All other statistical tools are described in
the appropriate Materials and Methods section and in the Results section.
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